{"disease":{"id":"male-patterned-baldness","name":"Male Patterned Baldness","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"finasteride","indication_name":"Male Patterned Baldness","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propecia","generic_name":"finasteride","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9","drug_class":"5-alpha-reductase inhibitor","quality_score":null,"revenue":null,"mechanism":"Selective type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), treating BPH and male pattern hair loss."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}